NEW YORK, NY--(Marketwired - Nov 18, 2014) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. ("iBio" or the "Company") (NYSE MKT: IBIO) securities between October 13, 2014 and October 23, 2014.

For more information, click here:

The Complaint alleges that during the Class Period, the Company issued materially false and misleading statements to investors by wrongfully suggesting that the Company's Launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The Complaint alleges that when the true facts were revealed, the price of the Company's stock fell significantly, damaging investors.

If you suffered a loss in iBio you have until December 23, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510